ROCO
4113
Market cap108mUSD
Oct 08, Last price
14.95TWD
1D
1.01%
1Q
-0.66%
Jan 2017
67.04%
IPO
177.88%
Name
We&Win Diversification Co Ltd
Chart & performance
P/E
—
P/S
5.66
EPS
—
Div yield, %
5.69%
Shrs. gr., 5y
1.83%
Rev. gr., 5y
22.63%
Revenues
610m
-89.32%
Net income
-100m
L
CFO
-2.92b
L
Dividend
Aug 28, 20250.85 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
We & Win Diversification Co., Ltd., a company headquartered in Kaohsiung City, Taiwan, primarily focuses on the acquisition, rental, and sale of real estate properties across the island. Beyond its core property activities, the firm's operations encompass a diverse range of sectors, including investments in public infrastructure projects, the development of new towns and communities, the wholesale distribution of medical equipment, and various international trade endeavors. Established in 1987, the entity originally traded as Oncoprobe Biotech Inc. before adopting its current designation of We & Win Diversification Co., Ltd. in 2009.
Key people
Mei-Li Lin
Deputy General Manager-Finance Division, Head of Finance · since 2026
Xin-Jie Lu
Deputy General Manager-Development Division, Chief Information Security Officer · since 2023
Sheng-Wen Zheng
Deputy General Manager · since 2020
Nai-Chi Kung
Corporate Governance Officer · since 2014
Chairman of the Board, General Manager · since 2004
Director · since 2011
Independent Director · since 2014
Xin-Zhong Lai
Independent Director · since 2020
Chung-Zhi Wang
Independent Director · since 2017
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||